Amedisys, Inc. (NASDAQ:AMED) Stock Position Raised by BlackRock Inc.

Posted by Defense World Staff on Mar 10th, 2023

BlackRock Inc. lifted its stake in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 1.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,960,416 shares of the health services provider’s stock after acquiring an additional 57,035 shares during the quarter. BlackRock Inc. owned 12.19% of Amedisys worth $383,327,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Raymond James & Associates lifted its holdings in shares of Amedisys by 6.5% in the first quarter. Raymond James & Associates now owns 11,101 shares of the health services provider’s stock valued at $1,913,000 after purchasing an additional 680 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Amedisys by 9.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock valued at $413,000 after purchasing an additional 202 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Amedisys by 22.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock valued at $590,000 after purchasing an additional 620 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Amedisys by 40.4% in the first quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock valued at $1,310,000 after purchasing an additional 2,193 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Amedisys by 6.4% in the first quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock valued at $2,287,000 after purchasing an additional 803 shares in the last quarter. 96.17% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Michael Paul North sold 5,908 shares of the firm’s stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $86.43, for a total value of $510,628.44. Following the sale, the insider now directly owns 4,164 shares of the company’s stock, valued at $359,894.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMED shares. SVB Leerink reduced their target price on Amedisys from $96.00 to $85.00 and set a “market perform” rating for the company in a report on Thursday, January 5th. Stephens restated an “equal weight” rating and issued a $95.00 target price on shares of Amedisys in a report on Thursday, February 16th. Royal Bank of Canada cut their price objective on Amedisys from $114.00 to $111.00 and set an “outperform” rating for the company in a report on Tuesday, February 21st. StockNews.com upgraded Amedisys from a “hold” rating to a “buy” rating in a report on Friday, February 17th. Finally, Oppenheimer cut their price objective on Amedisys from $145.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, January 19th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $121.53.

Amedisys Price Performance

NASDAQ AMED opened at $82.54 on Friday. Amedisys, Inc. has a fifty-two week low of $79.30 and a fifty-two week high of $179.91. The stock’s 50-day moving average is $90.33 and its two-hundred day moving average is $95.55. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.09 and a quick ratio of 1.09. The firm has a market cap of $2.69 billion, a P/E ratio of 22.68, a price-to-earnings-growth ratio of 2.41 and a beta of 1.04.

Amedisys (NASDAQ:AMED – Get Rating) last issued its quarterly earnings results on Thursday, February 16th. The health services provider reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.13. The company had revenue of $562.10 million for the quarter, compared to the consensus estimate of $560.46 million. Amedisys had a return on equity of 15.44% and a net margin of 5.34%. The firm’s revenue was up .5% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. On average, analysts anticipate that Amedisys, Inc. will post 4.26 earnings per share for the current fiscal year.

Amedisys Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.

Amedisys, Inc. (NASDAQ:AMED) Stock Position Raised by BlackRock Inc.

Insider Activity

Analysts Set New Price Targets

Amedisys Price Performance

Amedisys Profile

See Also

You might be interested in: